Kinnate Biopharma Inc. to Participate in the 2022 Wells Fargo Securities Healthcare Conference
August 30, 2022 16:05 ET
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief...
Kinnate Biopharma Inc. Announces Second Quarter 2022 Financial Results and Recent Corporate Updates
August 11, 2022 16:05 ET
|
Kinnate Biopharma
Phase 1 clinical trial for KIN-2787, the company’s investigational pan-RAF inhibitor, was initiated in Taiwan by Kinnjiu Biopharma Inc., Kinnate’s China joint ventureU.S. Food and Drug Administration...
Kinnate Biopharma Inc. to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 02, 2022 16:05 ET
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief...
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
June 01, 2022 16:05 ET
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will...
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022
May 26, 2022 17:00 ET
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates
May 12, 2022 16:05 ET
|
Kinnate Biopharma
Initial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022 Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to...
Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248
April 18, 2022 08:00 ET
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting
April 08, 2022 16:30 ET
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates
March 28, 2022 16:05 ET
|
Kinnate Biopharma
Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022 Initiation of the...
Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting
March 08, 2022 18:00 ET
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...